Furthermore, high-dose galectin-9 administration demonstrated anti-tumor effects in CTCL, underscore its potential as a therapeutic target (Nakajima et al., 2019). Here, LGALS9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.